Immunotherapy before surgery for early-stage endometrial cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests whether an immunotherapy combination can help shrink or control endometrial cancer so that surgery might not be needed. It is for people whose tumors have a specific genetic feature (dMMR/MSI-H) that may respond well to this treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a type of endometrial cancer that is not carcinosarcoma and is early enough to be completely removed by surgery.
- Your tumor must be dMMR or MSI-H, which means it has a specific genetic feature that may make immunotherapy more effective.
- You cannot have had any chemotherapy, radiation, or other cancer treatment in the past 5 years.
- You must be in good overall health, with no major heart, lung, or autoimmune conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a drug called dostarlimab (an immunotherapy that boosts your immune system to fight cancer) before and after surgery can help treat advanced endometrial cancer. It is for people with stage 3 or 4 endometrial cancer who haven't had treatment yet and may be eligible if their tumor has a specific marker called mismatch repair deficiency.
This trial studies nivolumab (an immune therapy that helps your body recognize cancer) after surgery for endometrial cancer that has mismatch-repair deficiency (MMR-d) or high microsatellite instability (MSI-H). It aims to lower the chance the cancer comes back by treating “leftover risk” after the tumor is removed.
This trial tests a combination of three drugs (pembrolizumab, lenvatinib, and an immune booster called N-803) plus a personalized vaccine made from your own cells, all aimed at helping your immune system fight advanced or metastatic endometrial cancer that has HER2 protein on its surface.
This trial tests a new immunotherapy drug (QL1706) for people with advanced endometrial cancer whose previous immunotherapy stopped working. It aims to see if this different approach can help when standard treatments have failed.
This trial tests a new study medicine called PF-08634404 when combined with standard chemotherapy for people with advanced or recurrent endometrial cancer that is MMR-proficient (meaning the DNA repair system is working normally). The goal is to see if adding this medicine helps shrink or control the cancer better than chemotherapy alone.
This trial tests whether giving a combination of two immunotherapy drugs before surgery can help shrink stomach cancer and reduce the chance of it coming back. It is for people whose tumors have a specific genetic feature called MSI-H or dMMR, which often responds well to immunotherapy.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.